直接抗病毒药物治疗肝硬化HCV/HIV合并感染队列的疗效与安全性
这项西班牙13家医院的多中心前瞻性分析纳入2015年1月至12月启动DAA治疗的170例肝硬化HCV/HIV合并感染患者,总体SVR12为92.9%,初治者SVR12高于经治者(97.5% vs 88.8%,P=0.026),治疗期间肝失代偿4例(2.4%),33例配对LSM下降5.6 kPa(95%CI 1.8-9.2;P=0.004)。
要点
- 肝硬化HCV/HIV合并感染者DAA治疗总体SVR12达92.9%。
- 经治者SVR12低于初治者(88.8% vs 97.5%,P=0.026)。
- 病毒清除与肝硬度显著下降相关(5.6 kPa,95%CI 1.8-9.2)。
核心结论
- 在该肝硬化HCV/HIV合并感染队列中,DAA方案高度安全有效,病毒清除与肝硬度显著下降相关。
研究设计与样本
- 西班牙13家医院的多中心前瞻性分析,纳入2015年1月至12月启动DAA联合治疗的肝硬化HCV/HIV合并感染患者170例。
主要发现
- 总体SVR12为92.9%(158/170),各基因型间无差异。
- 经治者SVR12为88.8%,初治者为97.5%(P=0.026)。
- 治疗失败包括复发7例(4.1%)、失访2例(1.2%)、毒性停药1例(0.6%)、肝失代偿1例(0.6%)和病毒突破1例(0.6%)。
- 治疗期间肝失代偿4例(2.4%),肝性脑病和腹水各2例。
- 33例配对LSM下降5.6 kPa(95%CI 1.8-9.2;P=0.004)。
关键数值与推荐
- 基线中位LSM为20.6 kPa(IQR 16.1-33.7),log10 HCV-RNA为6.1 IU/mL(IQR 5.7-6.5)。
- Child-Pugh A级127例(74.7%),既往肝失代偿28例(16.5%)。
- 经治89例(52.4%),其中无应答者36例(40.4%)。
- 主要方案:索磷布韦/来迪派韦+利巴韦林43例(25.3%)、索磷布韦+西美瑞韦+利巴韦林34例(20%)、索磷布韦/来迪派韦26例(15.3%)、索磷布韦+达拉他韦+利巴韦林25例(14.7%)。
临床怎么用
- 肝硬化HCV/HIV合并感染者可考虑DAA治疗,但经治者需关注较低SVR12并加强监测。
- 治疗期间需监测肝失代偿表现如肝性脑病和腹水。
- 治疗后肝硬度下降可作为病毒清除的获益指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: New direct-acting antiviral agents (DAAs) have shown great efficacy and tolerability in clinical trials and real-life cohorts. However, data are scarce regarding efficacy and safety in cirrhotic HCV/HIV-coinfected patients. METHODS: A multicentre prospective analysis was performed in 13 Spanish hospitals, including all cirrhotic HCV/HIV-coinfected patients starting DAA combinations from January to December 2015. Sustained virological response 12 weeks after treatment (SVR12) was analysed. Withdrawal due to toxicity and/or hepatic decompensation and change in liver stiffness measurement (LSM) after HCV treatment were evaluated. RESULTS: Patients (n = 170) were mostly male (n = 125; 74.3%) with the following HCV genotype (Gt) distribution: Gt-1a, 68 (40%); Gt-1b, 21 (12.4%); Gt-4, 47 (27.6%); and Gt-3, 26 (15.3%). Baseline median LSM was 20.6 kPa (IQR 16.1-33.7) and log10 HCV-RNA 6.1 IU/mL (IQR 5.7-6.5). Most patients had a Child-Pugh class A score (n = 127; 74.7%) and 28 (16.5%) had prior hepatic decompensation. There were 89 (52.4%) pretreated patients with 40.4% (n = 36) of null responders. Preferred regimens were as follows: sofosbuvir/ledipasvir + ribavirin, 43 (25.3%) patients; sofosbuvir + simeprevir + ribavirin, 34 (20%); sofosbuvir/ledipasvir, 26 (15.3%) and sofosbuvir + daclatasvir + ribavirin, 25 (14.7%). Overall SVR12 was 92.9% (158/170), without differences between genotypes. Pretreated patients had lower SVR12 rates compared with naive (88.8% versus 97.5%; P = 0.026). Treatment failures were as follows: 7 (4.1%) relapses; 2 (1.2%) lost to follow-up; 1 (0.6%) toxicity-related discontinuation; 1 (0.6%) hepatic decompensation; and 1 (0.6%) viral breakthrough. On-treatment hepatic decompensation was recorded in four (2.4%) patients (encephalopathy and ascites, two each). Paired LSM in 33 patients showed a decrease of 5.6 kPa (95% CI 1.8-9.2; P = 0.004). CONCLUSIONS: In our cohort of cirrhotic HCV/HIV-coinfected patients, DAAs were highly safe and efficacious. Viral eradication was associated with a significant decrease in liver stiffness.
引用
- Navarro J, Laguno M, Vilchez HH, et al. Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients. J Antimicrob Chemother. 2017. PMID: 29091196. doi:10.1093/jac/dkx223
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。